KR20140060274A - 안구용 서방성 단백질 전달 제형 및 이의 제조방법 - Google Patents

안구용 서방성 단백질 전달 제형 및 이의 제조방법 Download PDF

Info

Publication number
KR20140060274A
KR20140060274A KR1020147000443A KR20147000443A KR20140060274A KR 20140060274 A KR20140060274 A KR 20140060274A KR 1020147000443 A KR1020147000443 A KR 1020147000443A KR 20147000443 A KR20147000443 A KR 20147000443A KR 20140060274 A KR20140060274 A KR 20140060274A
Authority
KR
South Korea
Prior art keywords
formulation
tocopherol
atec
plga
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147000443A
Other languages
English (en)
Korean (ko)
Inventor
버넌 쥐. 웡
루이스 엘. 우드
글렌 티. 황
Original Assignee
램스코르 인코포레이티드
아이콘 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 램스코르 인코포레이티드, 아이콘 바이오사이언스, 인크. filed Critical 램스코르 인코포레이티드
Publication of KR20140060274A publication Critical patent/KR20140060274A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147000443A 2011-06-10 2012-06-11 안구용 서방성 단백질 전달 제형 및 이의 제조방법 Withdrawn KR20140060274A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (1)

Publication Number Publication Date
KR20140060274A true KR20140060274A (ko) 2014-05-19

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147000443A Withdrawn KR20140060274A (ko) 2011-06-10 2012-06-11 안구용 서방성 단백질 전달 제형 및 이의 제조방법

Country Status (22)

Country Link
US (1) US9814773B2 (cg-RX-API-DMAC10.html)
EP (1) EP2717914B1 (cg-RX-API-DMAC10.html)
JP (1) JP6339011B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140060274A (cg-RX-API-DMAC10.html)
CN (1) CN103945865B (cg-RX-API-DMAC10.html)
AU (1) AU2012304909B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013031685B1 (cg-RX-API-DMAC10.html)
CA (1) CA2838289C (cg-RX-API-DMAC10.html)
CY (1) CY1122771T1 (cg-RX-API-DMAC10.html)
DK (1) DK2717914T3 (cg-RX-API-DMAC10.html)
ES (1) ES2761340T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20192276T1 (cg-RX-API-DMAC10.html)
HU (1) HUE047737T2 (cg-RX-API-DMAC10.html)
IN (1) IN2013MN02384A (cg-RX-API-DMAC10.html)
LT (1) LT2717914T (cg-RX-API-DMAC10.html)
MX (1) MX359119B (cg-RX-API-DMAC10.html)
PL (1) PL2717914T3 (cg-RX-API-DMAC10.html)
PT (1) PT2717914T (cg-RX-API-DMAC10.html)
RS (1) RS60051B1 (cg-RX-API-DMAC10.html)
SI (1) SI2717914T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202000021T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013036309A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
KR20230104762A (ko) * 2015-03-18 2023-07-10 산텐 세이야꾸 가부시키가이샤 서방성 의약 조성물

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913336C (en) * 2013-05-24 2020-12-15 Icon Bioscience, Inc. Use of sustained release dexamethasone in post-cataract surgery inflammation
JP6629840B2 (ja) * 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
US10786515B2 (en) * 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
EP3749386B1 (en) 2018-02-09 2026-04-15 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
EP4652999A3 (en) 2018-05-01 2026-02-18 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2019213326A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
ES2672806T3 (es) * 2009-07-03 2018-06-18 Armbruster Biotechnology Gmbh Injerto óseo y material biocompuesto

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230104762A (ko) * 2015-03-18 2023-07-10 산텐 세이야꾸 가부시키가이샤 서방성 의약 조성물
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지

Also Published As

Publication number Publication date
PL2717914T3 (pl) 2020-05-18
EP2717914B1 (en) 2019-10-30
NZ619707A (en) 2015-01-30
HRP20192276T1 (hr) 2020-05-15
RS60051B1 (sr) 2020-04-30
SMT202000021T1 (it) 2020-03-13
WO2013036309A3 (en) 2013-05-10
CA2838289A1 (en) 2013-03-14
CN103945865B (zh) 2016-10-26
CA2838289C (en) 2019-09-10
WO2013036309A2 (en) 2013-03-14
MX2013014461A (es) 2014-05-14
US20140140992A1 (en) 2014-05-22
IN2013MN02384A (cg-RX-API-DMAC10.html) 2015-06-12
SI2717914T1 (sl) 2020-07-31
BR112013031685A2 (pt) 2017-02-07
JP6339011B2 (ja) 2018-06-06
PT2717914T (pt) 2019-12-18
DK2717914T3 (da) 2020-01-20
AU2012304909B2 (en) 2017-06-08
LT2717914T (lt) 2020-03-25
JP2014516087A (ja) 2014-07-07
CY1122771T1 (el) 2021-05-05
EP2717914A2 (en) 2014-04-16
US9814773B2 (en) 2017-11-14
HUE047737T2 (hu) 2020-05-28
CN103945865A (zh) 2014-07-23
AU2012304909A1 (en) 2013-12-19
MX359119B (es) 2018-09-14
EP2717914A4 (en) 2015-05-13
ES2761340T3 (es) 2020-05-19
BR112013031685B1 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
EP2717914B1 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CN101890167B (zh) 可方便植入的缓释药物组合物
US11883525B2 (en) Bioerodible polyester polymer axitinib ocular implants and related methods of use
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
US20090092650A1 (en) Sustained Delivery Formulations of Octreotide Compounds
US20150037429A1 (en) Controlled Release Microparticles
US20150273066A1 (en) Conveniently implantable sustained release drug compositions
HK1196081A (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HK1196081B (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
Fan et al. Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits
WO2025075991A1 (en) Cai-loaded bioerodible implant and methods of use thereof
TWI439293B (zh) 便利植入式持續釋放型藥學組合物
HK1107672B (en) Conveniently implantable sustained release drug compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid